Barclays
UNCY icon

Barclays’s Unicycive Therapeutics UNCY Stock Holding History

Barclays’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Sell
39,001
-10,999
-22% -$81.1K ﹤0.01% 3769
2026
Q1 		$329K Buy
50,000
+49,920
+62,400% +$327K ﹤0.01% 3429
2025
Q4 		$462 Hold
80
– – ﹤0.01% 5099
2025
Q3 		$349 Hold
80
– – ﹤0.01% 5219
2025
Q2 		$382 Buy
+80
New +$495 ﹤0.01% 5085

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Barclays's UNCY Position: Q2 2026 in Review

Barclays reduced its Unicycive Therapeutics (UNCY) stake by 22% in Q2 2026, selling an estimated $81.1K and leaving 39,001 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #3769.

Barclays first reported a position in UNCY in Q2 2025 and has held it in 5 quarters since. The position peaked at $329K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Barclays held 39,001 shares of Unicycive Therapeutics worth $183K as of Q2 2026.
  • Barclays sold 10,999 Unicycive Therapeutics shares in Q2 2026, an estimated $81.1K.
  • Unicycive Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3769 holding.
  • Barclays first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Unicycive Therapeutics position peaked at $329K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.